Wee1 Inhibitor Gets Win in Tough-to-Treat Ovarian Cancer
January 25, 2021 5:00 pmBy Ian Ingram
Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed.
For the primary endpoint of progression-free survival … Read more